Spiriva Respimat

(Tiotropium bromide)

Spiriva Respimat

Drug updated on 11/17/2023

Dosage FormInhalation spray (oral; 1.25 mcg or 2.5 mcg (2.5 mcg or 5 mcg))
Drug ClassAnticholinergic
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • The long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations.
  • The long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Spiriva Respimat (tiotropium bromide) Prescribing Information.2021Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Asthma guideline updates.2022ACSAP: Pulmonary Care